Is Sermorelin FDA Approved? The Full Regulatory Story
Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.
In this article
Sermorelin FDA Status at a Glance
Currently FDA Approved?
No. Product discontinued in 2008.
Previously FDA Approved?
Yes. Geref/Geref Diagnostic approved 1997.
Why Discontinued?
Commercial decision by EMD Serono, not safety.
Current Availability
Compounded medication with prescription
Active Molecule
Sermorelin acetate (GHRH 1-29), 29 amino acids
FDA-Approved GH Alternative
Tesamorelin (Egrifta), approved 2010
The Short Answer
Sermorelin was FDA-approved. It is not anymore. The branded product Geref was approved in 1997 and voluntarily discontinued by the manufacturer in 2008. Today Sermorelin is only available as a compounded medication. The molecule itself has the strongest regulatory pedigree of almost any peptide in compounded use, because it actually went through the full FDA approval process and was used clinically for over a decade.
Key Point
Sermorelin's discontinuation was a business decision, not a safety one. No FDA safety warning, recall, or adverse event signal led to its removal from the market. The manufacturer simply chose to stop making it.
The Full Regulatory History
1982
GHRH Discovered
Roger Guillemin's lab at the Salk Institute isolates growth hormone-releasing hormone from a pancreatic tumor. Guillemin had already won the Nobel Prize in 1977 for earlier hypothalamic hormone discoveries.
1997
FDA Approval
The FDA approves sermorelin acetate under two brand names. Geref Diagnostic: for evaluating pituitary growth hormone secretion capacity. Geref: for treating idiopathic growth hormone deficiency in children with open epiphyses. Manufacturer: Serono (later EMD Serono).
2008
Voluntary Discontinuation
EMD Serono discontinues both Geref and Geref Diagnostic for commercial reasons. No safety concerns, no FDA action. Manufacturing simply stops. Sermorelin transitions to compounding pharmacy availability.
1980s
Sermorelin Synthesized
Scientists determine that the first 29 amino acids of GHRH (the 1-29 fragment) retain full biological activity. This fragment is synthesized as sermorelin acetate. Its shorter length makes it easier to manufacture than full-length GHRH (44 amino acids).
1997-2008
Clinical Use
Geref is prescribed for pediatric GH deficiency and used off-label by practitioners for adult GH optimization. Geref Diagnostic is used in endocrinology clinics to test pituitary function. Safety profile is well established over a decade of clinical use.
2008-Present
Compounded Era
Sermorelin becomes one of the most widely compounded peptides in the United States. Licensed pharmacies prepare it under 503A and 503B regulations. The molecule and its effects are well characterized from its FDA-approved years.
Why Geref Was Discontinued
Drug discontinuation for commercial reasons is more common than most patients realize. A pharmaceutical company may stop manufacturing a drug because the market is too small, a newer product replaces it in their portfolio, manufacturing costs increase, or strategic priorities shift after a merger or acquisition.
In Sermorelin's case, EMD Serono was shifting its focus toward other therapeutic areas. The pediatric GH deficiency market was relatively small, and practitioners were increasingly using Sermorelin off-label for adult applications that Serono had no financial incentive to support. The company made a business decision to allocate manufacturing capacity elsewhere.
Importantly, there was no FDA safety warning, no black box update, no recall, and no adverse event signal that prompted the discontinuation. The FDA did not pull Sermorelin from the market. The manufacturer chose to stop selling it. This is a critical distinction that gets lost in casual conversations about the drug's regulatory status.
Sermorelin Today: Compounded Medication
When a previously FDA-approved drug is discontinued and no generic equivalent exists, compounding pharmacies can legally prepare it under federal law. This is exactly what happened with Sermorelin. The molecule, its dosing, its effects, and its safety profile are all well characterized from years of FDA-approved use. The only thing that changed is who manufactures it.
Compounded sermorelin uses the same active molecule: sermorelin acetate, the 29-amino-acid GHRH fragment. It is prepared by licensed 503A or 503B pharmacies, prescribed by licensed providers, and subject to state and federal pharmacy regulations. PeRx ships sermorelin fully reconstituted and ready to use.
Sermorelin vs Other GH Peptides: Regulatory Comparison
| Sermorelin | CJC-1295/Ipamorelin | Tesamorelin (Egrifta) | |
|---|---|---|---|
| FDA Approved? | Previously (1997-2008) | Never | Yes (2010, current) |
| Clinical Trial Data | Full NDA package (Phase 1-3) | Phase 2 (CJC-1295), preclinical (Ipamorelin) | Two Phase 3 RCTs, 816 patients |
| Current Availability | Compounded only | Compounded only | Branded + compounded |
| Mechanism | GHRH receptor agonist (short-acting) | GHRH + ghrelin receptor (dual pathway) | GHRH receptor agonist (long-acting) |
| Half-Life | 10-20 minutes | Days (CJC-1295 with DAC) | ~26 minutes (DPP-IV protected) |
| Regulatory Pedigree | Strongest among compounded peptides | Standard compounded | Gold standard (current approval) |
Sermorelin's Advantage
Among compounded peptides, Sermorelin has the strongest regulatory history. It is the only widely used compounded peptide that actually went through the full FDA approval process, was commercially manufactured, and was prescribed clinically for over a decade before being discontinued.
Frequently Asked Questions
Ready to get started?
Pharmaceutical-grade Sermorelin, prescribed by a licensed provider and shipped to your door. Fully reconstituted and ready to use.
View SermorelinMedical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.